Navigation Links
Hope For Patients With Prostate Cancer

Researchers say new research might help extend the survival for men with advanced prostate cancer.In one study, researchers studied more // than 600 men with hormone-refractory prostate cancer. About half of the men were treated with the drug combination docetaxel and estramustine while the other half was treated with standard care, which is mitoxantrone and prednisone.

Researchers found improved survival among the men who received the docetaxel/estramustine treatment and it was also found that there was a greater significance in survival rates . Men in the docetaxel/estramustine group were found to have about a 20-percent reduced risk of death.Thus researchers say that this shows that docetaxel can effectively treat [this type of] prostate cancer. Side effects include nausea, vomiting and infections.

In a second study, researchers studied men with prostate cancer who received one of three treatments: docetaxel plus prednisone every week; a higher dose of docetaxel plus prednisone every three weeks, or mitoxantrone plus prednisone weekly. Researchers say survival among the men who received the docetaxel/prednisone treatment every three weeks was significantly greater (18.9 months) than the other two treatment regimens (17.4 months and 16.5 months respectively). Results show there was also a greater drop in PSA level among men in this treatment group, as well as less pain and improved quality of life.Thus researchers say it is indeed a reason for celebration and also optimism as it can serve as platform for further research.
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: